Table 1. Correlation between GalNAc-T3 or -T6 expression and clinicopathologic variables.
| Total | GalNAc-T3 positive, n (%) | GalNAc-T6 positive n (%) | |||
|---|---|---|---|---|---|
| Variables | n (%) | Positive, n=54 | P | Positive, n=36 | P |
| Age, years | 0.331 | 0.934 | |||
| ⩽60 | 17 (24.3) | 14 (82.4) | 7 (41.2) | ||
| >60 | 53 (75.7) | 40 (75.5) | 29 (54.7) | ||
| Sex | 0.751 | 0.842 | |||
| Male | 40 (57.1) | 32 (80.0) | 22 (55.0) | ||
| Female | 30 (42.9) | 22 (73.3) | 14 (46.7) | ||
| Tumour differentiation | 0.001 | 0.001 | |||
| Well, moderately | 61 (87.1) | 51 (83.6) | 36 (59.0) | ||
| Poorly | 9 (12.9) | 3 (33.3) | 0 (0.0) | ||
| Tumour size, pathologic a | 0.751 | 0.044 | |||
| ⩽3.5 cm | 30 (58.8) | 24 (80.0) | 21 (70.0) | ||
| >3.5 cm | 21 (41.2) | 16 (57.1) | 9 (42.9) | ||
| N classification | 0.085 | 0.760 | |||
| Negative | 26 (37.1) | 23 (88.5) | 14 (53.8) | ||
| Positive | 44 (62.9) | 31 (70.5) | 22 (50.0) | ||
| Stage (AJCC) | 0.679 | 0.043 | |||
| I–II | 51 (72.9) | 40 (78.4) | 30 (58.8) | ||
| III–IV | 19 (27.1) | 14 (73.7) | 6 (31.6) | ||
| Margin status | 0.607 | 0.161 | |||
| Negative | 39 (55.7) | 31 (79.5) | 23 (59.0) | ||
| Positive | 31 (44.3) | 23 (74.2) | 13 (41.9) | ||
| Lymphatic invasion | 0.269 | 0.954 | |||
| Absent | 4 (5.7) | 4 (100.0) | 2 (50.0) | ||
| Present | 66 (94.3) | 50 (75.8) | 34 (51.5) | ||
| Vascular invasion | 0.173 | 0.009 | |||
| Absent | 18 (25.7) | 16 (88.9) | 14 (77.8) | ||
| Present | 52 (74.3) | 38 (73.1) | 22 (42.3) | ||
| Perineural invasion | 0.676 | 0.066 | |||
| Absent | 3 (4.3) | 2 (66.7) | 0 (0.0) | ||
| Present | 67 (95.7) | 52 (77.6) | 36 (100.0) | ||
| GalNAc-T3 expression | — | 0.002 | |||
| Negative | 16 (22.9) | — | 3 (18.6) | ||
| Positive | 44 (77.1) | — | 33 (75.0) | ||
| GalNAc-T6 expression | 0.002 | — | |||
| Negative | 34 (48.6) | 21 (61.8) | — | ||
| Positive | 36 (51.4) | 33 (91.7) | — |
Abbreviation: AJCC=American Joint Committee on Cancer.
a
On 51 resectable tumours.